

# PDE Inhibitors - Pipeline Insight, 2022

<https://marketpublishers.com/r/P5DA0F45505EN.html>

Date: January 2022

Pages: 120

Price: US\$ 2,500.00 (Single User License)

ID: P5DA0F45505EN

## Abstracts

This report can be delivered to the clients within 3-4 working days

DelveInsight's, "PDE Inhibitors - Pipeline Insight, 2022" report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in PDE Inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

### Geography Covered

Global coverage

### PDE Inhibitors Understanding

#### PDE Inhibitors: Overview

Phosphodiesterase inhibitors (PDE inhibitors) are a class of agents acting on specific phosphodiesterase enzymes in target cells and are FDA approved for the management of chronic obstructive pulmonary disease, erectile dysfunction, pulmonary arterial hypertension, psoriasis, psoriatic arthritis, and atopic dermatitis. Phosphodiesterase enzymes' essential role serves to separate the phosphate group from the target cell and decrease cyclic adenosine monophosphate (cAMP) or cyclic guanosine monophosphate (cGMP). The inhibition of these enzymes further prevents the degradation of cAMP or cGMP, exhibiting smooth muscle relaxation, vasodilatory, and bronchodilatory effects. Hypersensitivity is an absolute contraindication to all phosphodiesterase inhibitors. Nitrites are contraindicated to use alongside PDE-5

inhibitors: sildenafil, tadalafil, vardenafil, and avanafil, as they may result in severe hypotension. Relative contraindication such as pre-existing cardiovascular disease, resting hypotension, and anti-hypertensive use require evaluation before phosphodiesterase inhibitor use.

'PDE Inhibitors - Pipeline Insight, 2022' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the PDE Inhibitors pipeline landscape is provided which includes the disease overview and PDE Inhibitors treatment guidelines. The assessment part of the report embraces, in depth PDE Inhibitors commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, PDE Inhibitors collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

## Report Highlights

The companies and academics are working to assess challenges and seek opportunities that could influence PDE Inhibitors R&D. The therapies under development are focused on novel approaches to treat/improve PDE Inhibitors.

## PDE Inhibitors Emerging Drugs Chapters

This segment of the PDE Inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

## PDE Inhibitors Emerging Drugs

### ARQ-151: Arcutis Biotherapeutics

Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase type 4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and

chronic obstructive pulmonary disease (COPD). Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis. Roflumilast is 25–300X more potent than the two other FDA-approved PDE4 inhibitors used in dermatology and has a well-established safety profile with more than 1 million patient years of exposure in clinical use.

### Ensifentrine: Verona Pharma

Ensifentrine is a first-in-class, inhaled, dual inhibitor of the phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) enzymes. This dual inhibition enables it to combine bronchodilator and anti-inflammatory properties in one compound, differentiating it from existing drug classes used to treat COPD, including corticosteroids, beta2-agonists and anti-muscarinics. It is currently in Phase III stage of development for Chronic obstructive pulmonary disease and is being developed Verona Pharma.

Further product details are provided in the report.....

### PDE Inhibitors: Therapeutic Assessment

This segment of the report provides insights about the different PDE Inhibitors drugs segregated based on following parameters that define the scope of the report, such as:

#### Major Players in PDE Inhibitors

There are approx. 40+ key companies which are developing the therapies for PDE Inhibitors. The companies which have their PDE Inhibitors drug candidates in the most advanced stage, i.e. Pre-registration include, Arcutis Biotherapeutics.

#### Phases

DelveInsight's report covers around 40+ products under different phases of clinical development like

#### Late stage products (Phase III)

Mid-stage products (Phase II)

Early-stage product (Phase I) along with the details of

Pre-clinical and Discovery stage candidates

Discontinued & Inactive candidates

Route of Administration

PDE Inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

Oral

Parenteral

Intravenous

Subcutaneous

Topical.

Molecule Type

Products have been categorized under various Molecule types such as

Monoclonal Antibody

Peptides

Polymer

Small molecule

Gene therapy

## Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

## PDE Inhibitors: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses PDE Inhibitors therapeutic drugs key players involved in developing key drugs.

## Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging PDE Inhibitors drugs.

## PDE Inhibitors Report Insights

PDE Inhibitors Pipeline Analysis

Therapeutic Assessment

Unmet Needs

Impact of Drugs

## PDE Inhibitors Report Assessment

Pipeline Product Profiles

Therapeutic Assessment

Pipeline Assessment

Inactive drugs assessment

## Unmet Needs

### Key Questions

#### Current Treatment Scenario and Emerging Therapies:

How many companies are developing PDE Inhibitors drugs?

How many PDE Inhibitors drugs are developed by each company?

How many emerging drugs are in mid-stage, and late-stage of development for the treatment of PDE Inhibitors?

What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the PDE Inhibitors therapeutics?

What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?

What are the clinical studies going on for PDE Inhibitors and their status?

What are the key designations that have been granted to the emerging drugs?

### Key Players

Arcutis Biotherapeutics

Chiesi Farmaceutici

Imara Inc

Verona Pharma

Eisai Inc

vTv Therapeutics

Tetra Therapeutics

Palbiofarma

### Key Products

ARQ-151

CHF-6001

IMR-687

Ensifentrine

E 2027

HPP-737

BPN-14770

BTX-2640

PBF-999

## Contents

Introduction

Executive Summary

PDE Inhibitors: Overview

- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management

Pipeline Therapeutics

- Comparative Analysis

Therapeutic Assessment

- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type

Late Stage Products (Phase III)

- Comparative Analysis

Ensifentrine: Verona Pharma

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Mid Stage Products (Phase II)

- Comparative Analysis

IMR-687: Imara Inc

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Early stage products (Phase I)

- Comparative Analysis

Drug Name: Company Name

- Product Description
- Research and Development
- Product Development Activities



Drug profiles in the detailed report.....

Preclinical stage products

- Comparative Analysis

BTX-2640: BioTheryX

- Product Description
- Research and Development
- Product Development Activities

Drug profiles in the detailed report.....

Inactive Products

- Comparative Analysis

PDE Inhibitors Key Companies

PDE Inhibitors Key Products

PDE Inhibitors- Unmet Needs

PDE Inhibitors- Market Drivers and Barriers

PDE Inhibitors Key Companies

Appendix

## List Of Tables

### LIST OF TABLES

- Table 1 Total Products for PDE Inhibitors
- Table 2 Late Stage Products
- Table 3 Mid Stage Products
- Table 4 Early Stage Products
- Table 5 Pre-clinical & Discovery Stage Products
- Table 6 Assessment by Product Type
- Table 7 Assessment by Stage and Product Type
- Table 8 Assessment by Route of Administration
- Table 9 Assessment by Stage and Route of Administration
- Table 10 Assessment by Molecule Type
- Table 11 Assessment by Stage and Molecule Type
- Table 12 Inactive Products

## List Of Figures

### LIST OF FIGURES

- Figure 1 Total Products for PDE Inhibitors
- Figure 2 Late Stage Products
- Figure 3 Mid Stage Products
- Figure 4 Early Stage Products
- Figure 5 Preclinical and Discovery Stage Products
- Figure 6 Assessment by Product Type
- Figure 7 Assessment by Stage and Product Type
- Figure 8 Assessment by Route of Administration
- Figure 9 Assessment by Stage and Route of Administration
- Figure 10 Assessment by Molecule Type
- Figure 11 Assessment by Stage and Molecule Type
- Figure 12 Inactive Products

## I would like to order

Product name: PDE Inhibitors - Pipeline Insight, 2022

Product link: <https://marketpublishers.com/r/P5DA0F45505EN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/P5DA0F45505EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970